| Li, Wei |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype |
|
|
| Recruiting | 4 | 24000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 TT Genotype | 06/29 | 06/29 | | |
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype |
|
|
| Recruiting | 4 | 32000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL) | 06/29 | 06/29 | | |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects |
|
|
| Recruiting | 3 | 312 | RoW | Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999） | Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang | Advanced HBV-Related Hepatocellular Carcinoma (HCC) | 12/22 | 12/22 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
NCT05545137: Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection |
|
|
| Completed | 3 | 299 | RoW | Pivmecillinam hydrochloride tablets, Selexid®, Fosfomycin Tromethamine Granules, Monurol® | Benova (Tianjin) Innovative medicine Research Co., Ltd. | Uncomplicated Urinary Tract Infection | 02/24 | 02/24 | | |
| Active, not recruiting | 3 | 160 | Europe, Japan, US, RoW | efgartigimod PH20 SC, Prednisone | argenx, argenx BV | Bullous Pemphigoid | 01/26 | 03/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
| Recruiting | 2/3 | 104 | RoW | B007, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
NCT06454357: A Clinical Study of B007 in the Treatment of Pemphigus. |
|
|
| Recruiting | 2/3 | 132 | RoW | B007 | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Pemphigus | 12/26 | 12/26 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
HERO-KC23, NCT06375707: Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer |
|
|
| Recruiting | 2 | 144 | RoW | physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS, Ribociclib combined with NSAI±OFS | The First Affiliated Hospital with Nanjing Medical University, Zhejiang Cancer Hospital | Advanced Breast Cancer | 11/25 | 12/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06543992: Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis |
|
|
| Recruiting | 2 | 22 | RoW | Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir | The First Affiliated Hospital with Nanjing Medical University, The Affiliated Brain Hospital of Nanjing Medical University | Leptomeningeal Metastasis of Breast Cancer | 12/26 | 12/26 | | |
NCT06656624: Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) |
|
|
| Recruiting | 2 | 190 | RoW | Ribociclib combined with AI±OFS, physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS | The First Affiliated Hospital with Nanjing Medical University, Yidu Central Hospital of Weifang, Affiliated Hospital of Jiangnan University, The Affiliated Jiangyin Hospital of Southeast University Medical College | Advanced Breast Cancer | 12/25 | 12/25 | | |
NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 10/24 | 11/24 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
NCT06001086: A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer |
|
|
| Recruiting | 2 | 70 | RoW | Disitamb Vedotin ,pyrotinib, Regular Visits | The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Wenzhou Medical University | Breast Cancer | 08/26 | 12/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
TRIGGERCD8, NCT06468358: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 194 | RoW | LB1410, LB4330 | L & L biopharma Co., Ltd., Shanghai China, Shanghai East Hospital | Solid Tumor | 12/26 | 12/27 | | |
| Recruiting | 1/2 | 56 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumor | 12/24 | 12/24 | | |
NCT05519059: Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer |
|
|
| Completed | 1 | 15 | RoW | Pelareorep, Paclitaxel | Adlai Nortye Biopharma Co., Ltd. | Advanced or Metastatic Breast Cancer | 09/22 | 05/23 | | |
NCT03634839: Effects of E-cigarette Flavors on Youth TCORS 2.0 |
|
|
| Completed | 1 | 42 | US | Flavoring Agents, Cooling flavor, Nicotine, Nicotine concentration | Yale University, National Institute on Drug Abuse (NIDA) | Nicotine Use Disorder | 06/23 | 07/23 | | |
| Recruiting | 1 | 18 | RoW | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection, BRL-201 | Bioray Laboratories, Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences, Zhejiang University, Wuhan Union Hospital, China | Non-hodgkin Lymphoma,B Cell | 01/24 | 03/24 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
NCT05357651: A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） |
|
|
| Recruiting | 1 | 100 | RoW | LB1410 | L & L biopharma Co., Ltd., Shanghai China | Solid Tumor, Lymphoma | 12/24 | 03/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia |
|
|
| Enrolling by invitation | 1 | 9 | RoW | BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University | Beta-Thalassemia | 08/25 | 09/26 | | |
NCT06015568: Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation |
|
|
| Not yet recruiting | 1 | 172 | RoW | MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | 11/28 | 07/29 | | |
NCT03147014: Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease |
|
|
| Recruiting | N/A | 600 | RoW | Maternal hyperoxygenation | Beijing Anzhen Hospital | Hypoplastic Left Heart Syndrome, Aortic Coarctation, Atrial Septal Aneurysm | 12/21 | 12/22 | | |
NCT04307030: Study on AI Recognition System Of Heart Sound In Congenital Heart Disease Screening |
|
|
| Recruiting | N/A | 5000 | RoW | Heart Auscultation and Echocardiography | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Congenital Heart Disease in Children | 12/21 | 06/23 | | |
NCT04469387: Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion |
|
|
| Recruiting | N/A | 200 | RoW | Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis, Responsible segments fused | Peking University Third Hospital | Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease, Degeneration Spine | 08/22 | 08/32 | | |
| Recruiting | N/A | 286 | RoW | Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation | Ruijin Hospital | Atrial Fibrillation, Persistent, Arrhythmias, Cardiac | 07/25 | 01/26 | | |
NCT05375123: Reference Range for Tissue Motion Tracking of Mitral Annulus Displacement in Chinese Han Singleton Pregnancies |
|
|
| Recruiting | N/A | 660 | RoW | Ultrasound image acquisition | First Hospital of China Medical University | Pregnancy | 06/23 | 06/24 | | |
NCT05547841: Normal Reference Value for Echocardiography in Chinese Han Pregnancies |
|
|
| Recruiting | N/A | 680 | RoW | Echocardiography acquisition | First Hospital of China Medical University | Pregnancy | 08/23 | 08/24 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
NCT05764941: Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 100 | RoW | Inetetamab, Pyrotinib, Vinorelbine | The First Affiliated Hospital with Nanjing Medical University | Breast Neoplasms | 03/24 | 03/24 | | |
| Recruiting | N/A | 280 | US | EndoAVF Creation | C. R. Bard | Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula | 06/26 | 09/26 | | |
NCT05932693: Effect of Different E-cigarette Cooling Flavors on Adults' Sensory Experience TCORS 3.0 |
|
|
| Recruiting | N/A | 30 | US | E-liquid coolant (WS-3, 0.05%), Flavor type, E-liquid coolant (WS-3, 0.1%), E-liquid coolant (WS-3, 0.5%), E-liquid coolant (WS-3, 1.0%), E-liquid coolant (WS-3, 2.0%), E-liquid coolant (menthol, 0.05%), E-liquid coolant (menthol, 0.1%), E-liquid coolant (menthol, 0.5%), E-liquid coolant (menthol, 1.0%), E-liquid coolant (menthol, 2.0%), E-liquid coolant (WS-23, 0.05%), E-liquid coolant (WS-23, 0.1%), E-liquid coolant (WS-23, 0.5%), E-liquid coolant (WS-23, 1.0%), E-liquid coolant (WS-23, 2.0%), E-liquid coolant (WS-23, 4.0%) | Yale University, National Institute on Drug Abuse (NIDA) | E-Cig Use | 01/26 | 01/26 | | |
NCT05978752: Clinical Study on Endoscopic Management of GOV1 Esophagogastric Varices |
|
|
| Not yet recruiting | N/A | 57 | NA | Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices, Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices, Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Jinhua Hospital Affiliated to Zhejiang University, Lanxi People's Hospital, Lishui Country People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University | Esophageal and Gastric Varices | 06/25 | 11/25 | | |
| Recruiting | N/A | 366 | RoW | Cardiopulmonary rehabilitation, Usual care | The First Affiliated Hospital with Nanjing Medical University | Critical Illness | 06/25 | 12/25 | | |
NCT06015165: Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery |
|
|
| Recruiting | N/A | 216 | RoW | Analgesia plan for Anes. Group, Anes Group, Analgesia plan for Surg. Group, Surg. Group, Multi-modal analgesia during the surgery, Intraoperative analgesic plan | China-Japan Friendship Hospital | Postoperative Pain | 06/25 | 10/25 | | |
NCT05987293: A Single-center, Prospective Study for Mechanism and Risk Factors of Tracheal Tube-related Tongue Injury |
|
|
| Active, not recruiting | N/A | 94 | RoW | Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure. | China-Japan Friendship Hospital | Tracheal Tube-related Tongue Injury | 08/24 | 12/25 | | |
| Recruiting | N/A | 1332 | RoW | The lying flat (0°-10°) head position for 72 hours, The The head elevation (30°-40°) position for 72 hours | Zhengzhou Yuan | Stroke, Acute, Endovascular Therapy | 11/25 | 04/26 | | |
| Recruiting | N/A | 200000 | Europe, Canada, RoW | | Population Health Research Institute, Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Ontario | Cardiovascular Diseases, Risk Factor, Cardiovascular, Health Behavior, Environmental Exposure, Lung Diseases, Cancer, Injuries, Renal Disease, Communicable Disease | 12/30 | 12/30 | | |
NCT04688437: Correlation Among Standing-sitting Sagittal Spinal Alignment, Paravertebral Muscle and Postoperative Clinical Outcomes in Patients With Adult Degenerative Scoliosis |
|
|
| Not yet recruiting | N/A | 200 | RoW | standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination | Peking University Third Hospital | Degenerative Scoliosis | 12/21 | 01/24 | | |
THALIA-01, NCT05231863: Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study |
|
|
| Recruiting | N/A | 100 | RoW | TKIs | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 12/22 | 12/22 | | |
NCT04467944: Effect of Pre-existing Adjacent Segment Degeneration on Long-term Effectiveness After Lumbar Fusion Surgery |
|
|
| Recruiting | N/A | 210 | RoW | Pre-existing degenerative factors at adjacent segment | Peking University Third Hospital | Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease, Degeneration Spine | 12/22 | 12/32 | | |
NCT05444647: Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study |
|
|
| Recruiting | N/A | 100 | RoW | stool and blood collection | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 05/24 | 06/25 | | |
| Not yet recruiting | N/A | 1000 | NA | gastric contrast ultrasound | The First Hospital of Jilin University | Transabdominal Gastric Contrast Ultrasound | 06/24 | 12/24 | | |
ALOT-BC1, NCT05334147: Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer |
|
|
| Not yet recruiting | N/A | 315 | NA | | The First Affiliated Hospital with Nanjing Medical University | HER2-negative Breast Cancer | 02/25 | 09/25 | | |
| Wang, Fei |
NCT06269445: The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer |
|
|
| Recruiting | 4 | 20 | RoW | Icaritin Combined With Bevacizumab and FOLFIRI | Sir Run Run Shaw Hospital | Colorectal Cancer | 02/25 | 02/26 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05369078: Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group | Newsoara Biopharma Co., Ltd. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
NCT06561997: Enhancing Thoracolumbar Burst Fracture Treatment |
|
|
| Completed | N/A | 182 | RoW | Robot-assisted, Free-hand | Peng Liu | Surgery | 06/19 | 06/20 | | |
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 900 | RoW | | Qilu Hospital of Shandong University, Bayer | Type 2 Diabetes Mellitus, Poor Glycemic Control | 11/20 | 12/22 | | |
NCT04658992: The Registration on the Use of Feilike Heji in Minors |
|
|
| Recruiting | N/A | 3000 | RoW | | China Academy of Chinese Medical Sciences | Bronchial Asthma | 12/21 | 03/22 | | |
NCT05949736: Effect of Music Therapy in Medical Students (EMTMS) |
|
|
| Recruiting | N/A | 200 | RoW | The Online intervention platform | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Insomnia | 08/23 | 05/25 | | |
| Recruiting | N/A | 60 | RoW | Group Cognitive Behavioral Therapy (GCBT) | Jiangsu Province Nanjing Brain Hospital | Mental Suffering | 09/23 | 01/24 | | |
NCT05648539: Effect of Music Therapy in Mental Subhealth (EMTMS) |
|
|
| Recruiting | N/A | 150 | RoW | The mini apps named "SOUL GYM" on the Wechat | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety | 10/23 | 10/27 | | |
| Recruiting | N/A | 120 | RoW | Active rTMS, VISHEE Magneuro stimulator, Sham rTMS | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 07/24 | 07/24 | | |
NCT06238869: Online Mental Health Interventions for Children and Adolescents (OMHICA) |
|
|
| Enrolling by invitation | N/A | 7000 | RoW | Computerized Cognitive Behavioral Therapy, Music Therapy, Health education | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Stress, Insomnia | 09/25 | 12/25 | | |
NCT05681364: Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study |
|
|
| Not yet recruiting | N/A | 300 | NA | metabonomics | Peking University Third Hospital | Chronic Obstructive Pulmonary Disease, Bronchiectasis | 12/24 | 12/24 | | |
PRHDTDCSTMDE, NCT05498441: Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode |
|
|
| Recruiting | N/A | 120 | RoW | High-Definition Transcranial Direct Current Stimulation (HD-tDCS), Antipsychotics, mood stabilizers, etc. | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 12/24 | 12/24 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
